The DNA sequencing group has narrowed its losses and improved its gross margin, but a volatile share price reflects lingering doubts about the pace of Revenue growth.
Oxford Nanopore Technologies (LSE:ONT) has spent much of 2026 trying to rebuild credibility with investors. The FTSE 250 gene sequencing specialist reported half-year results showing revenue of £116.7 million for the six months to 30 June, up 11%, or 12% at constant currency. Losses narrowed substantially as cost discipline took hold, and the shares rose 9% to 133.2p on the day, although they remained around 36% lower than a year earlier.
The improvement was most visible in profitability measures. The adjusted loss before interest, tax, Depreciation and Amortisation shrank to £22.1 million from £48.3 million a year earlier, while the pre-tax loss narrowed to £44.9 million from £69.0 million. Gross Margin rose to 62.2% from 58.2%, already in line with full-year guidance of around 62%.
Guidance and the road to breakeven
Oxford Nanopore continues to expect revenue growth of 16% to 20% at constant currency for 2026, which implies a meaningful acceleration in the second half from the first-half rate. Adjusted operating costs are expected to be flat to down 2% year on year. The chief executive said the company is tracking well towards adjusted EBITDA breakeven in the 2027 financial year, and the group is aiming for positive free Cash Flow in 2028.
Longer term, management has set a target of more than $700 million of revenue by 2030. Reaching that goal would require sustained growth well above the current run rate, which helps explain why investors remain cautious.
A difficult backdrop
The company's share price has been weighed down by a series of disappointments. Earlier in the year, Oxford Nanopore warned that first-half revenue would fall short of expectations, sending the shares sharply lower. It also trimmed its medium-term guidance, citing slower revenue growth, which weighed further on sentiment. The setbacks came after a period in which the company had said full-year revenue would be slightly ahead of hopes, illustrating how quickly sentiment can swing for a Business at this stage of development. For a company still loss-making at the operating level, small changes in revenue expectations can have an outsized effect on valuation, since much of the Investment case rests on growth several years into the future rather than on current earnings.
The wider life sciences tools market has also been challenging. Science funding pressures, particularly in the United States, and cautious spending by academic and biopharma customers have weighed on Demand across the sector. Oxford Nanopore's technology, which allows real-time sequencing of long DNA and RNA strands on devices ranging from handheld units to high-throughput platforms, is increasingly used in clinical, applied and biopharma settings, and management sees these markets as key drivers of future growth.
What comes next
The key question for the remainder of 2026 is whether the second half delivers the acceleration needed to meet full-year revenue guidance. A shortfall would likely reignite concerns about the company's targets, while a healthy finish would support the narrative that cost discipline and commercial focus are paying off. Investors will also be monitoring cash burn closely, given that profitability remains some way off.
A trading update around the turn of the year and full-year results in early 2027 will provide the next major checkpoints. Progress in clinical and applied markets, along with any new partnerships, will be watched as indicators of the company's longer-term potential.






Please wait processing your request...